Sorafenib in patients with progressive epithelioid hemangioendothelioma: A phase 2 study by the French Sarcoma Group (GSF/GETO)

Cancer

Volumn 119, Issue 14, 2013, Pages 2639-2644

  Chevreau, Christine ^a   Le Cesne, Axel ^b   Ray Coquard, Isabelle ^c   Italiano, Antoine ^d   Cioffi, Angela ^b   Isambert, Nicolas ^e   Robin, Yves Marie ^f   Fournier, Charles ^f   Clisant, Stéphanie ^f   Chaigneau, Loic ^g   Bay, Jacques Olivier ^h   Bompas, Emmanuelle ⁱ   Gauthier, Eric ^j   Blay, Jean Y ^f   Penel, Nicolas ^f,k  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT BERGONIÉ   (France)

^e Department of Medical Oncology   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^h CENTRE JEAN PERRIN   (France)

ⁱ Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^j Bayer HealthCare   (France)

^k UNIV LILLE   (France)

more..

Author keywords

epithelioid hemangioendothelioma; orphan diseases; phase 2 trial; sarcoma; sorafenib

Indexed keywords

DOXORUBICIN; SORAFENIB; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHROMYALGIA; ARTICLE; BLEEDING; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONVULSION; DELIRIUM; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EPITHELIOID HEMANGIOENDOTHELIOMA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HEMANGIOENDOTHELIOMA; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX RATIO; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR VASCULARIZATION;

EPITHELIOID HEMANGIOENDOTHELIOMA; ORPHAN DISEASES; PHASE 2 TRIAL; SARCOMA; SORAFENIB;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HEAD AND NECK NEOPLASMS; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RARE DISEASES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879693329     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28109     Document Type: Article

References (23)

1. Fletcher CD,. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006; 48: 3-12.
2. Ducimetiere F, Lurkin A, Ranchere-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing [serial online]. PLoS One. 2011; 6: e20294.
3. D'Adamo R,. Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol. 2011; 38: S19-S29.
4. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P,. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011; 22: 1266-1272.
5. Penel N, Marreaud S, Robin YM, Hohenberger P,. Angiosarcoma: state of the art and perspectives. Crit Rev Oncol Hematol. 2011; 80: 257-263.
6. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008; 26: 5269-5274.
7. Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012; 17: 260-266.
8. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133-3140.
9. Mehrabi A, Kashfi A, Fonouni H, et al. Primary malignant hepatic epithelioid hemangioendothelioma. Cancer. 2006; 107: 2108-2121.
10. Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid haemangioendothelioma in 21 patients, including 3 with partial spontaneous regression. Eur Respir J. 1998; 12: 89-96.
11. Emamaullee JA, Edgar R, Toso C, et al. Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management. Liver Transplant. 2010; 16: 191-197.
12. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K,. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol. 1996; 148: 763-775.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216.
14. Cioffi A, Italiano A, Penel N, et al. Metastatic epithelioid hemangioendothelioma (EHE): role of systemic therapy and survival [abstract]. J Clin Oncol. 2011; 29S. Abstract 10079.
15. Radzikowska E, Szczepulska-Wojcik E, Chabowski M, et al. Pulmonary epithelioid hemangioendothelioma-interferon 2-alpha treatment-case report. Pneumol Alergol Pol. 2008; 76: 281-285.
16. Calabro L, Di Giacomo AM, Altomonte M, et al. Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? J Exp Clin Cancer Res. 2007; 26: 145-150.
17. Mascarenhas RC, Sanghvi AN, Friedlander L, et al. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology. 2004; 67: 471-475.
18. Raphael C, Hudson E, Williams L, Lester JF, Savage PM,. Successful treatment of metastatic hepatic epithelioid hemangioendothelioma with thamidomide: a case report [serial online]. J Med Case Rep. 2010; 4: 413.
19. Salech F, Valderrama S, Nervi B, et al. Thalidomide for the treatment of metastatic hepatic epithelioid hemangioendothelioma: a case report with a long term follow-up. Ann Hepatol. 2011; 10: 99-102.
20. Trautmann K, Bethke A, Ehninger G, Folprecht G,. Bevacizumab for recurrent hemangioendothelioma. Acta Oncol. 2011; 50: 153-154.
21. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013; 24: 257-263.
22. Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial. Invest New Drugs. 2011; 29: 481-488.
23. Rosner GL, Stadler W, Ratain MJ,. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002; 20: 4478-4484.